Stifel Nicolaus Boosts Enfusion (NYSE:ENFN) Price Target to $13.00

Enfusion (NYSE:ENFN) had its price target hoisted by Stifel Nicolaus from $11.00 to $13.00 in a research note issued to investors on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Enfusion Stock Up 27.3 %

NYSE ENFN opened at $13.69 on Wednesday. The company has a 50-day simple moving average of $9.64 and a two-hundred day simple moving average of $8.98. Enfusion has a 12-month low of $7.52 and a 12-month high of $13.69. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 342.34, a PEG ratio of 3.98 and a beta of 0.97.

Insider Buying and Selling at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 36.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enfusion

Hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in Enfusion by 251.4% in the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after acquiring an additional 61,554 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after purchasing an additional 70,367 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after buying an additional 61,032 shares during the period. TenCore Partners LP purchased a new position in shares of Enfusion during the third quarter valued at about $3,938,000. Finally, State Street Corp lifted its holdings in Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company’s stock worth $9,043,000 after buying an additional 21,729 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.